betulin 3-O-palmitate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: betulin 3-O-palmitate
• 英文别名: betulin-3-O-palmitate；Betulin palmitate；[(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-(hydroxymethyl)-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-yl] hexadecanoate
• 化学式: C₄₆H₈₀O₃
• 分子量: 681.139
• InChiKey: NAXJLYBHSMUSAV-JGYMROJHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  16.2
• 重原子数：
  49
• 可旋转键数：
  18
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  甲醇 、 betulin 3-O-palmitate 在 氢氧化钾 作用下， 反应 3.0h， 生成 棕榈酸甲酯 、 白桦脂醇
  参考文献：
  名称：

  New Triterpenoids from Gentiana lutea.

  摘要：

  从龙胆草的根茎和根中分离出了三种新的三萜类化合物，即 2,3-seco-3-oxours-12-en-2-oic acid、2,3-seco-3-oxoolean-12-en-2-oic acid 和 betulin 3-O-palmitate，以及五种已知的三萜类化合物。新化合物的结构是通过光谱和化学方法确定的。

  DOI：

  10.1248/cpb.51.89

文献信息

• Betulinol derivatives
  申请人：——

  公开号：US20030036540A1

  公开（公告）日：2003-02-20

  The present invention is directed to betulinol derivatives and betulinol-antibody conjugates having the formulae: 1 and HO-antibody-spacer-(A 2 ) n wherein A 1 is a moiety having the formula: 2 A 2 is a moiety having the formula: 3 n is an integer from 1 to 100; X and Y 1 are each independently selected from the group consisting of a hydroxy group, an alkoxy group, an alkanoyloxy group, and a-peptide-NHNH—C(O)-antibody-OH moiety; Y 2 is selected from the group consisting of a hydroxy group, an alkoxy group, and an alkanoyloxy group; and HO-antibody-H is an antibody and, in particular, betulinol dimethyl ether. Methods for making and using these derivatives and conjugates, as well as a method for making and using betulonic aldehyde, are also disclosed.

  本发明涉及具有以下式子的白桦醇衍生物和白桦醇-抗体偶联物：1和HO-抗体-间隔物-(A2)n其中，A1是具有以下式子的基团：2，A2是具有以下式子的基团：3，n是1到100之间的整数；X和Y1分别独立地选自羟基、烷氧基、烷酰氧基和-肽-NHNH-C（O）-抗体-OH基团的群；Y2选自羟基、烷氧基和烷酰氧基的群；HO-抗体-H是一种抗体，特别是白桦醇二甲醚。本发明还公开了制备和使用这些衍生物和偶联物的方法，以及制备和使用白桦酸醛的方法。
• Betulinol derivatives as anti-HIV agents
  申请人：Saxena B. Brij

  公开号：US20060154904A1

  公开（公告）日：2006-07-13

  The present invention relates to methods of treating HIV-1 infection in a subject. These methods involve administering to the subject with HIV-1 infection a therapeutically effective amount of a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection. Also disclosed are methods inhibiting HIV-1 activity in a cell. These methods involve providing a cell infected with HIV-1 and contacting the cell with a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell.

  本发明涉及治疗HIV-1感染的方法。这些方法涉及在有效治疗HIV-1感染的条件下向HIV-1感染的受试者注射一定量的结合或免疫结合的白桦醇衍生物化合物或其药学上可接受的盐或衍生物。本发明还揭示了一种抑制细胞中HIV-1活性的方法。这些方法涉及提供一种感染HIV-1的细胞，并在有效抑制细胞内HIV-1活性的条件下，将结合或免疫结合的白桦醇衍生物化合物或其药学上可接受的盐或衍生物与该细胞接触。
• BETULINOL DERIVATIVES
  申请人：——

  公开号：US20040001837A1

  公开（公告）日：2004-01-01

  The present invention is directed to betulinol derivatives and betulinol-antibody conjugates having the formulae: 1 and HO-antibody-spacer-(A 2 ) n wherein A 1 is a moiety having the formula: 2 A 2 is a moiety having the formula: 3 n is an integer from 1 to 100; X and Y 1 are each independently selected from the group consisting of a hydroxy group, an alkoxy group, an alkanoyloxy group, and a-peptide-NHNH—C(O)-antibody-OH moiety; Y 2 is selected from the group consisting of a hydroxy group, an alkoxy group, and an alkanoyloxy group; and HO-antibody-H is an antibody and, in particular, betulinol dimethyl ether. Methods for making and using these derivatives and conjugates, as well as a method for making and using betulonic aldehyde, are also disclosed.

  本发明涉及具有以下式子的白桦三萜衍生物和白桦三萜衍生物-抗体偶联物： 1 和 HO-抗体-间隔物-(A2)n 其中， A1是具有以下式子的基团：2 A2是具有以下式子的基团：3 n是从1到100的整数； X和Y1各自独立地选择自羟基、烷氧基、烷酰氧基和-肽-NHNH-C（O）-抗体-OH基团的群； Y2选择自羟基、烷氧基和烷酰氧基的群； HO-抗体-H是一种抗体，特别是白桦三萜二甲醚。本发明还公开了制备和使用这些衍生物和偶联物的方法，以及制备和使用白桦酮醛的方法。
• Anti-HIV-1 activity of betulinol derivatives
  申请人：Saxena B. Brij

  公开号：US20060019934A1

  公开（公告）日：2006-01-26

  The present invention relates to a method of inhibiting HIV-1 activity in a cell. This method involves providing a cell infected with HIV-1 and contacting the cell with a compound of Formula I where R 1 is —CH 3 , ═O, —OH, —OCH 3 , or —OC(O)CH 3 , and R 2 is —H, —CH 3 , —CHO, —CH 2 OH, —CH 2 OCH 3 , —CH 2 OC(O)CH 3 , —COCH 3 , or —COOH, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell. A method of treating HIV-1 infection in a subject is also disclosed. This method involves administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection.

  本发明涉及一种抑制细胞中HIV-1活性的方法。该方法包括提供一种感染HIV-1的细胞，将该细胞与式I化合物接触，其中R1为—CH3，═O，—OH，—O 或—OC（O） ，R2为—H，— ，—CHO，—CH2OH，—CH2O ，—CH2OC（O） ，—CO 或—COOH，或其药学上可接受的盐或衍生物，在有效条件下抑制细胞中的HIV-1活性。本发明还公开了一种治疗受HIV-1感染的主体的方法。该方法包括在有效条件下给予化合物I式的治疗有效量，或其药学上可接受的盐或衍生物，以治疗受HIV-1感染的主体。
• Betulinol Derivatives as Anti-Hiv Agents
  申请人：Saxena Brij B.

  公开号：US20080286291A1

  公开（公告）日：2008-11-20

  The present invention relates to methods of treating HIV-1 infection in a subject. These methods involve administering to the subject with HIV-1 infection a therapeutically effective amount of a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection. Also disclosed are methods inhibiting HIV-1 activity in a cell. These methods involve providing a cell infected with HIV-1 and contacting the cell with a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell.

  本发明涉及用于治疗HIV-1感染的方法。这些方法涉及向HIV-1感染的受试者施用治疗有效量的结合或免疫结合的白桦醇衍生物化合物，或其药学上可接受的盐或衍生物，在有效条件下治疗受试者的HIV-1感染。还公开了抑制细胞中HIV-1活性的方法。这些方法涉及提供一种感染HIV-1的细胞，并在有效条件下将结合或免疫结合的白桦醇衍生物化合物或其药学上可接受的盐或衍生物与细胞接触，以抑制细胞中的HIV-1活性。